(Q45999111)

English

Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose.

scientific article published on 30 March 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

human subject research project

0 references

pharmacodynamics

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

D J Dairaghi

1

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

P Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

Y Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

L C Seitz

4

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

D A Johnson

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

S Miao

6

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

L S Ertl

7

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

Y Zeng

8

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

J P Powers

9

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

A M Pennell

10

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

P Bekker

11

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

T J Schall

12

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

J C Jaen

13

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

language of work or name

0 references

publication date

30 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

Clinical Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

89

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

5

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

726-734

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

The many roles of chemokines and chemokine receptors in inflammation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Chemokines and their receptors: drug targets in immunity and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Maraviroc for previously treated patients with R5 HIV-1 infection

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Chemokine receptor antagonists: Part 1.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Microbes in gastrointestinal health and disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

CCR1 antagonists: what have we learned from clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Chemokine receptor antagonists: part 2.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

The role of chemokines in rheumatoid arthritis and osteoarthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Chemokines and leukocyte trafficking in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Chemokines and chemokine receptors in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Proteolytic activation of alternative CCR1 ligands in inflammation

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Identification of C-C chemokine receptor 1 (CCR1) as the monocyte hemofiltrate C-C chemokine (HCC)-1 receptor

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Chemokines and T lymphocytes: more than an attraction

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Anti-chemokine small molecule drugs: a promising future?

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001-2005.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Impact of digital ulcers on disability and health-related quality of life in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

CP-481,715, a potent and selective CCR1 antagonist with potential therapeutic implications for inflammatory diseases

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Evaluation of the effect of the specific CCR1 antagonist CP-481715 on the clinical and cellular responses observed following epicutaneous nickel challenge in human subjects.

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

Blockade of chemokine signaling in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

21 January 2018

MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

7 January 2021

based on heuristic

inferred from DOI database lookup

Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

7 January 2021

based on heuristic

inferred from DOI database lookup

CCR2 receptor blockade alters blood monocyte subpopulations but does not affect atherosclerotic lesions in apoE(-/-) mice

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2011.33

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/CLPT.2011.33

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 December 2017

http://europepmc.org/abstract/MED/21451509

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45999111&oldid=2144459871"